Brown Vance R 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) EVP Vance Brown Receives Awards & Exercises
What Happened
- Vance R. Brown, EVP, General Counsel and Corporate Secretary of Boston Scientific (BSX), received a total of 34,416 shares on Feb 13–16, 2026 through a mix of awards/grants and conversion/exercise of derivative awards (reported as code A and M).
- To satisfy tax-withholding obligations related to those awards/exercises (code F), 14,577 shares were surrendered/withheld at $74.73 per share, generating proceeds of $1,089,339. The awards themselves were reported with $0.00 acquisition price (typical for vested performance/RSU conversions).
Key Details
- Transaction dates: Feb 13, 14 and 16, 2026. Filing date: Feb 18, 2026 (filed timely).
- Gross shares acquired: 34,416 (29,608 from awards; 4,808 from conversion/exercise of derivatives).
- Shares disposed for tax payment: 14,577 at $74.73 each, total ~$1,089,339.
- Form codes: A = Award/Grant, M = Exercise/conversion of derivative, F = Payment of exercise price or tax liability (share withholding).
- Shares owned after the transactions: not stated in the filing.
- Notable footnotes:
- F1–F2: Awards include performance share units granted Feb 14, 2023; performance criteria and service condition were determined satisfied as of Feb 13, 2026.
- F3: Each restricted stock unit equals one share of common stock.
- F4–F6: Some shares are to be issued in four equal annual installments beginning on Feb 13, 2026; Feb 14, 2024; and Feb 16, 2023, respectively (per the filing).
Context
- This was primarily the vesting/settlement of performance shares and conversion/exercise of derivative awards, not an open-market buy or discretionary sale. The reported share disposals represent withholding to cover taxes (a routine administrative step), not an independent sale for cash proceeds beyond the tax obligation.
- Derivative entries (code M) reflect conversion/exercise of vested awards into common stock; the related F entries show shares withheld/surrendered to meet tax liabilities.
Insider Transaction Report
Form 4
Brown Vance R
EVP, GC and Corp. Secretary
Transactions
- Award
Common Stock
[F1]2026-02-13+14,804→ 49,209 total - Award
Common Stock
[F2]2026-02-13+14,804→ 64,013 total - Exercise/Conversion
Common Stock
[F3]2026-02-13+1,118→ 65,131 total - Tax Payment
Common Stock
2026-02-13$74.73/sh−12,792$955,946→ 52,339 total - Exercise/Conversion
Common Stock
[F3]2026-02-14+1,851→ 54,190 total - Tax Payment
Common Stock
2026-02-14$74.73/sh−895$66,883→ 53,295 total - Exercise/Conversion
Common Stock
[F3]2026-02-16+1,839→ 55,134 total - Tax Payment
Common Stock
2026-02-16$74.73/sh−890$66,510→ 54,244 total - Exercise/Conversion
Restricted Stock Units
[F3][F4]2026-02-13−1,118→ 3,357 totalExp: 2029-02-13→ Common Stock (1,118 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F5]2026-02-14−1,851→ 1,851 totalExp: 2027-02-14→ Common Stock (1,851 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F6]2026-02-16−1,839→ 0 totalExp: 2026-02-16→ Common Stock (1,839 underlying)
Footnotes (6)
- [F1]On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F2]On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
- [F3]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
- [F5]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
- [F6]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Signature
/s/ Susan Thompson, Attorney-in-Fact|2026-02-18